Paolo Patri

Stevanato Group, S.p.A.

Chief Technology Officer

Paolo Patri is the Chief Technology Officer with Stevanato Group, S.p.A., where he is responsible for R&D and CDMO services for drug delivery devices. Mr. Patri has over 20 years of experience in all aspects of pharmaceutical development and manufacturing operations.

Prior to joining Stevanato Group, he was Chief Manufacturing Officer with Dompé, an Italian biopharmaceutical company that had a breakthrough drug, Oxervate, approved in 2018. Prior to Dompé, Mr. Patri was Head of Corporate Drug Development with Chiesi Farmaceutici (previously Zymenex), which has a pipeline of drugs for rare diseases. He has achieved global regulatory approvals for large molecules, small molecules and combination medicinal products through standard and accelerated programs. Examples of such approvals include Oxervate, Trimbow, Lamzede, Foster NEXThaler, Foster pMDI, Bethkis, Retavase, Peyona, Envarsus and Zeftera.